Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

Sponsor
National Cancer Center, Korea
Study ID
NCT01470716
Phase
PHASE2
Status
Unknown

Conditions

  • NSCLC Stage II
  • NSCLC, Stage IIIA

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    Neo-adjuvant Erlotinib treatment during maximum 8 weeks.

Study Details

This study examines preoperative Erlotinib in patients with operable stage II and IIIA Non-small-cell lung cancer (NSCLC) harboring EGFR mutations.

Key Dates

First listed
Nov 11, 2011
Start date
Jan 31, 2012
Status verified
Apr 2022
Primary completion
Dec 31, 2021
Completion
Jun 30, 2022

Study Design

Enrollment
26 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study arm
    Neo-adjuvant Erlotinib treatment arm.

Primary Outcome Measure

Progression-Free survival [ Time Frame: every 8 week ]

Related Studies